Proteins are extremely important in neuroscience, so BRAIN cannot neglect them. Proteome is a new word for an old thing, that is the “protein complement encoding by a genome” according Marc R. Wilkins who coined the term in 1994. The definition of proteomics varies depending on whom you ask, but most researchers agree that it is the study of the proteome, the collective body of proteins made by an organism’s cells and tissues. What is new, of course, is the perspective, now that Human Genome Project is completed and biotech is ready for the challenge.

(Terms ending in “-ome” and “omics” are proliferating, visit



The best thing to do, for knowing more about proteins, remains visiting independent scientists in their labs, but for knowing biotech’s “new thing”, you might visit these websites.




MSD Proteomics, Toronto, focuses on receptors and intracellular signaling.


SGX, San Diego, focuses on protein structure of key targets within protein families.


CELERA, Rockville, Md, focuses on disease related proteins that could be targeted by drugs.


CELLZOME, Heidelberg, Germany, focuses on cellular protein complexes and protein interactions.


HYBRIGENICS, Paris, France, focuses on drug targets.


CURAGEN, New Haven, Conn, holds a patent on the yeast two-hybrid method for outlining prot. networks.


GENEPROT, North Brunswick, NJ, second industrial-scale proteomics facility to open in 2002 in NJ.


LARGE SCALE BIOLOGY, Vacaville, CA, is building a linked family of comprehensive databases of the human proteome.


MYRIAD, Salt Lake City, focuses on enzymes and signaling circuits.


SYRRX, San Diego, focuses on three-dimensional protein structures to discover new drugs.






BM&L websites may provide links to other Internet sites only for the convenience of World Wide Web users. BM&L is not responsible for the availability or content of these external sites, nor does BM&L endorse, warrant or guarantee the products, services or information described or offered at these other Internet sites.